Ondansetron suppository: an effective treatment for the prevention of emetic disorders induced by cisplatin-based chemotherapy

P. Fumoleau(Institut Curie), J.-M. Paillarse, M Giovannini, B. Votan, F. Rolland(Institut de Cancérologie de l'Ouest)

Oral Oncology

September 1, 1997

10.1016/s1368-8375(97)00006-7

Cited by 11

Related Papers

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

|Journal of Clinical Oncology|2007|290

Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study

|Journal of Clinical Oncology|2008|226

Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer

|Journal of Clinical Oncology|2009|119

Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.

|PubMed|1998|114

LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial

|Annals of Oncology|2021|87